These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23786843)

  • 61. [Possibilities of remaxol in prevention of toxic hepatitis during chemotherapy for cancer patients].
    Cherenkov VG; Petrov AB; Vasil'eva TM; Strozhenkov MM
    Vopr Onkol; 2013; 59(3):369-74. PubMed ID: 23909040
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Third-line therapy for metastatic colorectal cancer.
    Gundgaard MG; Soerensen JB; Ehrnrooth E
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):1-13. PubMed ID: 17786445
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer].
    Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC
    Ai Zheng; 2006 Aug; 25(8):1035-8. PubMed ID: 16965689
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [First-line chemotherapy for unresectable and metastatic colorectal cancer].
    Satoh T
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1372-5. PubMed ID: 25577805
    [No Abstract]   [Full Text] [Related]  

  • 65. [Chemotherapy-induced hepatotoxicity in patients with colorectal cancer liver metastases].
    Nakano H; Otsubo T; Koike A
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():536-40. PubMed ID: 22214018
    [No Abstract]   [Full Text] [Related]  

  • 66. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials.
    O'Neil BH; Goldberg RM
    Oncologist; 2008 Oct; 13(10):1074-83. PubMed ID: 18922828
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
    Nakamura M; Yamada Y; Muro K; Takahashi K; Baba H; Sasaki Y; Komatsu Y; Satoh T; Mishima H; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Future Oncol; 2015; 11(10):1471-8. PubMed ID: 25963425
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Drug-induced hepatotoxicity in cancer patients - implication for treatment.
    Vincenzi B; Armento G; Spalato Ceruso M; Catania G; Leakos M; Santini D; Minotti G; Tonini G
    Expert Opin Drug Saf; 2016 Sep; 15(9):1219-38. PubMed ID: 27232067
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Can we individualize chemotherapy for colorectal cancer?
    Chan R; Kerr DJ
    Ann Oncol; 2004 Jul; 15(7):996-9. PubMed ID: 15205190
    [No Abstract]   [Full Text] [Related]  

  • 70. Current trends in the chemotherapy of colorectal cancer.
    Berciano-Guerrero MA; Villa-Guzmán JC; Acosta-Guerrero R; Castañeda-Peñalvo G; Rodríguez-Flores J
    Curr Med Chem; 2012; 19(26):4414-30. PubMed ID: 22830343
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Review of third-line treatment strategies in refractory metastatic colorectal cancer.
    Barzi A
    Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):3-10. PubMed ID: 38805298
    [No Abstract]   [Full Text] [Related]  

  • 72. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity.
    Tao G; Huang J; Moorthy B; Wang C; Hu M; Gao S; Ghose R
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1109-1124. PubMed ID: 32841068
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Hepatotoxicity of chemotherapy].
    Sato Y; Kato J
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():369-74. PubMed ID: 25831785
    [No Abstract]   [Full Text] [Related]  

  • 74. Chemotherapy-Associated Hepatotoxicities.
    White MA; Fong Y; Singh G
    Surg Clin North Am; 2016 Apr; 96(2):207-17. PubMed ID: 27017860
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hepatotoxicity of targeted therapy for cancer.
    Lee KW; Chan SL
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):789-802. PubMed ID: 27187715
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The importance of keeping patients with metastatic colorectal cancer on treatment through the management of adverse events.
    Grothey A
    Clin Adv Hematol Oncol; 2020 Oct; 18 Suppl 16(10):15-19. PubMed ID: 33843851
    [No Abstract]   [Full Text] [Related]  

  • 77. Targeting the extracellular signature of metastatic colorectal cancers.
    Marchiò S; Arap W; Pasqualini R
    Expert Opin Ther Targets; 2009 Mar; 13(3):363-79. PubMed ID: 19236157
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is there a standard chemotherapeutic strategy in colorectal cancer?
    Zaniboni A; Meriggi F; Rizzi A; Mutti S; Morandi G
    Crit Rev Oncol Hematol; 1999 May; 30(3):229-38. PubMed ID: 10439068
    [No Abstract]   [Full Text] [Related]  

  • 79. [Chemotherapy-induced liver injury in children].
    Urrutia-Maldonado E; Abril-Molina A; Alés-Palmer M; Gómez-Luque JM; Muñoz de Rueda P; Ocete-Hita E
    An Pediatr (Engl Ed); 2019 Oct; 91(4):256-263. PubMed ID: 30777719
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of systemic chemotherapy on the liver.
    Ramadori G; Cameron S
    Ann Hepatol; 2010; 9(2):133-43. PubMed ID: 20526005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.